TROP2-directed antibody-drug conjugate composed of a human monoclonal antibody linked to the microtubule inhibitor prodrug MMAE; binds TROP2 on tumor cells, is internalized, and releases MMAE to disrupt microtubules and induce apoptosis.
TROP2-targeted human IgG1 antibody-drug conjugate linked via a beta-glucuronidase-cleavable linker to the microtubule inhibitor MMAE. After binding TROP2 and internalization, linker cleavage releases MMAE, which binds tubulin, inhibits microtubule polymerization, causes G2/M arrest, and induces apoptosis (with potential bystander killing).
NO
INDIRECT
LCB84 is a TROP2-targeted ADC. It binds TROP2, is internalized, and releases MMAE, which binds beta-tubulin (vinca site) to disrupt microtubules, causing G2/M arrest and apoptosis. Killing depends on TROP2-mediated delivery (with possible bystander effect), not on beta-tubulin expression alone.
Bispecific T-cell engager (CD3xCD19) immunotherapy that redirects patient T cells to kill CD19-positive leukemic B cells; used here for MRD-positive B-ALL.
Blinatumomab is a CD3×CD19 bispecific T‑cell engager that links patient T cells (via CD3) to CD19‑positive B cells, inducing MHC‑independent T‑cell activation and immune synapse formation, resulting in perforin/granzyme‑mediated cytotoxicity and serial killing of CD19+ leukemic cells.
YES
DIRECT
Blinatumomab bridges CD3 on T cells to CD19 on target cells, forming an immune synapse that activates T cells to release perforin and granzymes, causing cytolytic apoptosis of CD19+ cells.
Bispecific T-cell engager (CD3xCD19) immunotherapy that redirects patient T cells to kill CD19-positive leukemic B cells; used here for MRD-positive B-ALL.
Blinatumomab is a CD3×CD19 bispecific T‑cell engager that links patient T cells (via CD3) to CD19‑positive B cells, inducing MHC‑independent T‑cell activation and immune synapse formation, resulting in perforin/granzyme‑mediated cytotoxicity and serial killing of CD19+ leukemic cells.
NO
INDIRECT
Blinatumomab binds CD3 on T cells to recruit and activate them against CD19+ cells; T cells (CD3+) are not killed—activated T cells kill CD19+ targets via perforin/granzyme.
Gene-modified T lymphocytes engineered ex vivo to express a chimeric antigen receptor targeting CD19 with CD3ζ and costimulatory domains; administered as a single IV infusion after lymphodepleting chemotherapy to treat relapsed/refractory CD19+ B-cell malignancies.
Ex vivo–engineered T lymphocytes expressing a CD19‑specific chimeric antigen receptor with CD3ζ and costimulatory domains recognize CD19 on B‑cell malignancies and, upon CAR engagement, trigger TCR‑independent activation, proliferation, cytokine release, and perforin/granzyme‑mediated cytotoxicity to eliminate CD19+ tumor cells; prior lymphodepletion supports in vivo expansion and persistence.
YES
DIRECT
CD19 CAR-T cells bind CD19 on target cells, activate, and kill via T-cell effector functions—primarily perforin/granzyme-mediated cytolysis (and Fas/FasL), inducing apoptosis.
Gene-modified natural killer cells engineered ex vivo to express a chimeric antigen receptor targeting CD19; given as a single IV infusion to induce NK-mediated cytotoxicity against CD19+ B-cell malignancies.
Ex vivo gene-modified natural killer cells engineered to express a CD19-specific chimeric antigen receptor; CAR engagement of CD19 activates NK signaling (CD3zeta/costimulatory domains) to drive targeted lysis of CD19+ B cells via perforin/granzyme release and cytokine secretion.
YES
DIRECT
CAR-NK cells bind CD19 via the CAR, triggering NK activation and degranulation to kill CD19+ cells through perforin/granzyme-mediated cytolysis (and death receptor pathways).